


## Patent Claims

### 1. Compounds of the formula I



in which

X denotes H or F, Cl, Br, I, CN, OCN, SCN, COR<sup>2</sup>, COOR<sup>2</sup>, CONR<sup>2</sup>R<sup>3</sup>, imidazolyl, pyrazolyl, triazolyl or tetrazolyl,

Y denotes -CHR<sup>2</sup>-CHR<sup>2</sup>- or -CR<sup>2</sup>=CR<sup>2</sup>-,

Q denotes O, OH, NH, NH<sup>2</sup>, NR<sup>2</sup>R<sup>3</sup>, C=O, CHOH, CHNH<sub>2</sub>, C=NH, CHOR<sup>2</sup> or CNR<sup>2</sup>R<sup>3</sup>,

R<sup>1</sup> denotes branched or unbranched alkylcycloalkyl, alkaryl or alkheteroaryl, each of which is mono- or poly-substituted by X,

R<sup>2</sup> denotes H or linear or branched alkyl or alkaryl,

R<sup>3</sup> denotes H or R<sup>2</sup>,


and

m and n, independently of one another, denote 1, 2 or 3,

and salts, solvates, racemates, enantiomers and diastereomers thereof and mixtures thereof in all ratios.


### 2. Compounds of the formula I selected from a group consisting of the compounds I1 to I7:

5



11


10



12

15

20




13

25

30


35

5



14


10



15

15


20



16

25

30



17

35

3. Compounds of the formula I according to Claim 1 or 2 and physiologically acceptable salts and solvates thereof as medicaments.
- 5 4. Compounds of the formula I according to Claim 1 or 2 and physiologically acceptable salts and solvates thereof as medicaments having a 5-HT<sub>2A</sub> receptor-antagonistic action.
- 10 5. Medicaments according to Claim 4 for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, such as bulimia, panic attacks, anorexia nervosa, sleeping disorders, such as also sleep apnoea, of premenstrual syndrome, for the prophylaxis of and for combating the consequences of cerebral infarction phenomena, 15 such as strokes and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder (OCD).
- 20 6. Pharmaceutical composition comprising at least one medicament according to Claim 5 and optionally excipients and/or adjuvants and optionally other active ingredients.
- 25 7. Use of compounds according to Claim 1 or 2 and/or of physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT<sub>2A</sub> receptor-antagonistic action.
- 30 8. Use according to Claim 7 for the preparation of a medicament for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, eating disorders, such as bulimia, panic attacks, anorexia nervosa, sleeping disorders, such as also sleep apnoea, of premenstrual syndrome, for the prophylaxis of and for combating the consequences of cerebral infarction phenomena, such as strokes and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder 35 (OCD).